Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study
ConclusionCRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Hepatocellular Carcinoma | Liver Cancer | Peritoneal Cancer | Study | Surgery